Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

A unique genome in EBV-positive BL

Jonathan C. Strefford, David G. Oscier

Blood (2019) 133 (12): 1269–1270.

https://doi.org/10.1182/blood-2019-01-897603

Published: 2019

Journal Articles

Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project

Blood (2015) 126 (23): 4146.

https://doi.org/10.1182/blood.V126.23.4146.4146

Published: 2015

Journal Articles

ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome

Blood (2015) 126 (23): 1712.

https://doi.org/10.1182/blood.V126.23.1712.1712

Published: 2015

Journal Articles

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

Blood (2014) 124 (21): 76.

https://doi.org/10.1182/blood.V124.21.76.76

Published: 2014

Journal Articles

Tracking Subclonal Mutations in IGHV-Mutated CLL with Progressive Disease

Matthew JJ Rose-Zerilli, PhD, Gibson Jane, PhD, Jun Wang, PhD, William J Tapper, PhD, Helen Parker, PhD, Anton Parker, Zadie Davis, Anne Catherine Gardiner, Jade Forster, Andrew J Steele, PhD, Renata Walewska, Helen McCarthy, Andrew Collins, PhD, David G Oscier, MD, Jonathan C Strefford, PhD

Blood (2014) 124 (21): 1962.

https://doi.org/10.1182/blood.V124.21.1962.1962

Published: 2014

Journal Articles

Splicing Inhibition By Spliceostatin_A Is a Promising Therapeutic Strategy in Chronic Lymphocytic Leukaemia

Marta Larrayoz, PhD, Stuart Blakemore, Rachel Dobson, BSc, Matthew Rose-Zerilli, PhD, Renata Walewska, Matthew Blunt, PhD, Minoru Yoshida, PhD, David G Oscier, MD, Mark Cragg, PhD, Andrew J Steele, PhD, Jonathan C Strefford, PhD

Blood (2014) 124 (21): 3301.

https://doi.org/10.1182/blood.V124.21.3301.3301

Published: 2014

Journal Articles

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

Gillian G. Johnson, Ke Lin, Trevor F. Cox, Melanie Oates, David R. Sibson, Richard Eccles, Bryony Lloyd, Laura-Jayne Gardiner, Daniel F. Carr, Munir Pirmohamed, Jonathan C. Strefford, David G. Oscier, David Gonzalez de Castro, Monica Else, Daniel Catovsky, Andrew R. Pettitt

Blood (2013) 122 (26): 4253–4258.

https://doi.org/10.1182/blood-2013-07-516666

Published: 2013

Includes: Supplemental data

Journal Articles

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

David G. Oscier, Matthew J. J. Rose-Zerilli, Nils Winkelmann, David Gonzalez de Castro, Belen Gomez, Jade Forster, Helen Parker, Anton Parker, Anne Gardiner, Andrew Collins, Monica Else, Nicholas C. P. Cross, Daniel Catovsky, Jonathan C. Strefford

Blood (2013) 121 (3): 468–475.

https://doi.org/10.1182/blood-2012-05-429282

Published: 2013

Includes: Supplemental data

Journal Articles

Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations

Matthew Kaufman, MD, Xiao J. Yan, MD, PhD, Emanuela M. Ghia, PhD, Donna Neuberg, ScD, Laura Z. Rassenti, Ph.D., Kostas Stamatopoulos, MD, Paolo Ghia, MD, PhD, David G Oscier, MD, Frederic Davi, MD, PhD, Richard Rosenquist, MD, PhD, Chrysoula Belessi, MD, Zadie Davis, PhD, Andreas Agathangelidis, Neil Kay, MD, John C. Byrd, MD, Jennifer R Brown, MD, PhD, Kanti R. Rai, M.D., Thomas J. Kipps, M.D., Ph.D, Nicholas Chiorazzi, M.D.

Blood (2011) 118 (21): 288.

https://doi.org/10.1182/blood.V118.21.288.288

Published: 2011

Journal Articles

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

Sean H. Lim, Andrew T. Vaughan, Margaret Ashton-Key, Emily L. Williams, Sandra V. Dixon, H. T. Claude Chan, Stephen A. Beers, Ruth R. French, Kerry L. Cox, Andrew J. Davies, Kathleen N. Potter, C. Ian Mockridge, David G. Oscier, Peter W. M. Johnson, Mark S. Cragg, Martin J. Glennie

Blood (2011) 118 (9): 2530–2540.

https://doi.org/10.1182/blood-2011-01-330357

Published: 2011

Includes: Supplemental data

Journal Articles

The PARP inhibitor olaparib induces significant killing of ATM -deficient lymphoid tumor cells in vitro and in vivo

Victoria J. Weston, Ceri E. Oldreive, Anna Skowronska, David G. Oscier, Guy Pratt, Martin J. S. Dyer, Graeme Smith, Judy E. Powell, Zbigniew Rudzki, Pamela Kearns, Paul A. H. Moss, A. Malcolm R. Taylor, Tatjana Stankovic

Blood (2010) 116 (22): 4578–4587.

https://doi.org/10.1182/blood-2010-01-265769

Published: 2010

Includes: Supplemental data

Journal Articles

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A. Follows, Donald Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David G. Oscier, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Andy Rawstron, PhD, Christopher F.E. Pocock, MD, PhD

Blood (2010) 116 (21): 697.

https://doi.org/10.1182/blood.V116.21.697.697

Published: 2010

Journal Articles

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis

Gabrielle S. Sellick, Rachel Wade, Susan Richards, David G. Oscier, Daniel Catovsky, Richard S. Houlston

Blood (2008) 111 (3): 1625–1633.

https://doi.org/10.1182/blood-2007-08-110130

Published: 2008

Includes: Supplemental data

Journal Articles

HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia.

Gordon R. Strathdee, Tessa L. Holyoake, Alyson Sim, Anton Parker, David G. Oscier, Junia V. Melo, Stefan Meyer, Tim Eden, Anne M. Dickinson, Joanne Mountford, Heather G. Jorgensen, Richard Soutar, Robert Brown

Blood (2007) 110 (11): 2641.

https://doi.org/10.1182/blood.V110.11.2641.2641

Published: 2007

Journal Articles

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

Hazem A. Sayala, Paul Moreton, Ben Kennedy, Guy Lucas, Michael Leach, Saad M.B. Rassam, Andrew Haynes, Jane Tighe, David G. Oscier, Christopher Fegan, Andy C. Rawstron, Peter Hillmen

Blood (2007) 110 (11): 3114.

https://doi.org/10.1182/blood.V110.11.3114.3114

Published: 2007

Journal Articles

Cytogenetic Aberrations and Ig VH Gene Mutations of Clinically Benign CD5-Monoclonal B-Cell Lymphocytosis (MLUS).

Chen Wang, Dominick Amato, David G. Oscier, Zadie Davis, Sarah Mould, Elena Kolomietz, Jianing Zheng

Blood (2006) 108 (11): 4941.

https://doi.org/10.1182/blood.V108.11.4941.4941

Published: 2006

Journal Articles

ZAP-70 by Flow Cytometry: Comparison of Methodologies, and with IgVH Mutational and ZAP-70 Methylation Status.

Jenny A. Orchard, MD, Oliver G. Best, PhD, Rachel E. Ibbotson, PhD, Anton E. Parker, BSc, David G. Oscier, MD

Blood (2005) 106 (11): 1181.

https://doi.org/10.1182/blood.V106.11.1181.1181

Published: 2005

Journal Articles

DLEU2 , Located within the CLL 13q14 Deletion Locus, Encodes an Antisense RNA for the Putative Bicistronic RFP2/LEU5 Gene in Humans and Mouse.

Martin M. Corcoran, PhD, Marianne Hammarsund, PhD, Chaoyong Zhu, PhD, Mikael Lerner, BSc, Bagrat Kapanadze, PhD, Catharina Larsson, PhD, Lars Forsberg, PhD, Rachel E. Ibbotson, PhD, Stefan Einhorn, MD, David G. Oscier, MD, Dan Grander, MD, Olle Sangfelt, PhD

Blood (2004) 104 (11): 1540.

https://doi.org/10.1182/blood.V104.11.1540.1540

Published: 2004

Journal Articles

How Many Somatic Mutations Should We allow the Subset of Chronic Lymphocytic Leukemia with Unmutated IgVH Genes?.

Terry John Hamblin, MD, Jenny A. Orchard, MB, Zadie A. Davies, BSc, Rachel E. Ibbotson, PhD, Ann C. Gardiner, PhD, David G. Oscier, MB

Blood (2004) 104 (11): 767.

https://doi.org/10.1182/blood.V104.11.767.767

Published: 2004

Journal Articles

Gender as a Prognostic Factor in CLL. Biological Pointers to the Improved Outcome of Women.

Daniel Catovsky, MD, DSC, Estella Matutes, MD, PhD, Alison Morilla, BSc, Anna Burford, BSc, Vasantha Brito-Babapulle, PhD, Ilaria Del-Giudice, MD, Jennifer Orchard, MD, David G. Oscier, MD, Jim Halsey, PhD, Sue Richards, PhD

Blood (2004) 104 (11): 957.

https://doi.org/10.1182/blood.V104.11.957.957

Published: 2004

NARROW

A unique genome in EBV-positive BL

Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project

ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

Tracking Subclonal Mutations in IGHV-Mutated CLL with Progressive Disease

Splicing Inhibition By Spliceostatin_A Is a Promising Therapeutic Strategy in Chronic Lymphocytic Leukaemia

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

The PARP inhibitor olaparib induces significant killing of ATM -deficient lymphoid tumor cells in vitro and in vivo

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis

HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia.

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

Cytogenetic Aberrations and Ig VH Gene Mutations of Clinically Benign CD5-Monoclonal B-Cell Lymphocytosis (MLUS).

ZAP-70 by Flow Cytometry: Comparison of Methodologies, and with IgVH Mutational and ZAP-70 Methylation Status.

DLEU2 , Located within the CLL 13q14 Deletion Locus, Encodes an Antisense RNA for the Putative Bicistronic RFP2/LEU5 Gene in Humans and Mouse.

How Many Somatic Mutations Should We allow the Subset of Chronic Lymphocytic Leukemia with Unmutated IgVH Genes?.

Gender as a Prognostic Factor in CLL. Biological Pointers to the Improved Outcome of Women.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only